The US regulator approval is a significant milestone for Sun Pharma which paid $576 million (Rs 4600 crore) in January 2023 to acquire Concert Pharmaceuticals to gain access to deuruxolitinib, portrayed as a “potential best-in-class” therapy.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/oBQvxgS
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment